Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 63.58M | 63.52M | 377.71M | 60.92M | 51.84M | 24.00K |
Gross Profit | 47.08M | 41.59M | -59.67M | 38.34M | 35.40M | -103.16M |
EBITDA | -399.03M | -383.98M | -156.47M | -324.33M | -392.46M | -128.03M |
Net Income | -387.34M | -376.74M | -132.53M | -263.59M | -341.36M | -256.42M |
Balance Sheet | ||||||
Total Assets | 1.47B | 1.10B | 1.46B | 1.34B | 1.47B | 451.68M |
Cash, Cash Equivalents and Short-Term Investments | 1.22B | 850.74M | 1.19B | 1.08B | 965.65M | 299.67M |
Total Debt | 158.13M | 161.43M | 172.69M | 179.00M | 142.35M | 100.23M |
Total Liabilities | 343.78M | 370.28M | 478.38M | 608.24M | 647.72M | 206.12M |
Stockholders Equity | 1.12B | 733.54M | 981.33M | 733.47M | 826.74M | 245.56M |
Cash Flow | ||||||
Free Cash Flow | -360.96M | -356.19M | -182.93M | -26.42M | -113.08M | -112.10M |
Operating Cash Flow | -351.38M | -347.25M | -149.19M | 22.53M | -66.27M | -95.74M |
Investing Cash Flow | 113.38M | 185.01M | 71.84M | -461.34M | -294.14M | -100.12M |
Financing Cash Flow | 478.22M | 7.74M | 276.45M | 111.59M | 756.14M | 322.32M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
57 Neutral | $679.99M | ― | 181.41% | ― | 3055.71% | -18.80% | |
50 Neutral | $990.26M | ― | -57.92% | ― | -13.37% | 2.57% | |
46 Neutral | C$190.36M | -4.26 | -8.56% | 3.09% | 13.53% | -1.76% | |
45 Neutral | $1.69B | ― | -38.04% | ― | -82.38% | -164.76% | |
45 Neutral | $2.75B | ― | -62.46% | ― | ― | -43.10% | |
42 Neutral | $1.44B | ― | -69.30% | ― | ― | -68.13% |
On June 4, 2025, Beam Therapeutics held its annual meeting of stockholders, where key decisions were made regarding the company’s leadership and operations. The election of Class II directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation were all confirmed, reflecting strong shareholder support and potentially impacting the company’s governance and financial oversight.
The most recent analyst rating on (BEAM) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.